Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.42 |
| ▸ | CYP27A1 | Q02318 | 1/20 | 0.42 |
| ▸ | MPO | P05164 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MIF | P14174 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | BCL2 | P10415 | 1/20 | 0.41 |
| ▸ | PRNP | P04156 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7920369 | 0.84 | TDP1 (0.62) | METAP1CYP26A1MAPK14CYP27A1TDP1 | |
| SCHEMBL18535881 | 0.79 | METAP1 (0.66) | METAP1CYP1A2MPOCYP19A1ALDH1A1 | |
| SCHEMBL17978174 | 0.78 | KDM4E (0.51) | METAP1MAPK14TDP1L3MBTL1MIF | |
| SCHEMBL7913167 | 0.78 | APP (0.52) | METAP1MAPK14TDP1MAPTKDM4E | |
| SCHEMBL8321691 | 0.78 | METAP1 (0.56) | METAP1CYP1A2CYP2D6CYP26A1MPO | |
| SCHEMBL19810736 | 0.77 | MAPT (0.52) | METAP1CYP1A2MAPK14TDP1L3MBTL1 | |
| SCHEMBL7918568 | 0.75 | MAPT (0.53) | METAP1MAPK14TDP1MAPTCYP19A1 | |
| SCHEMBL17108416 | 0.75 | MPO (0.59) | METAP1CYP1A2CYP2D6CYP26A1MPO | |
| SCHEMBL15074186 | 0.75 | CYP26A1 (0.49) | METAP1CYP1A2CYP2D6CYP26A1MAPK14 | |
| SCHEMBL15395906 | 0.74 | METAP1 (0.54) | METAP1MAPK14MAPTCYP19A1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2328903-B1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETASECRETASE MODULATORS AND METHODS OF USE | AMGEN INC (US) | 2014-03-05 | — | — | EP | disclosed |
| US-8426447-B2 | Spiro-tricyclic ring compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426447-B2 | Spiro-tricyclic ring compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-20100087429-A1 | SPIRO-TRICYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100087429-A1 | SPIRO-TRICYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-04-08 | — | — | US | disclosed |
| WO-2010030954-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETASECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087429-A1 | SPIRO-TRICYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, BACE2, APP | METAP1 966/4885CYP1A2 258/4885CYP2D6 755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.